We repeated the replication analysis having performed mean-imputation of missing drug dose data, allowing a larger sample size of 4,855 to be analysed
Research shows that lean mass can comprise up to 40% of weight lost on GLP-1 therapy without adequate protein and resistance training
Surgical compared with nonoperative treatment for lumbar degenerative spondylolisthesis
Research has demonstrated that deep learning-based medical image recognition models outperform traditional methods, especially in tasks such as tumor detection and pathological image analysis, where these technologies are now widely used [130]
S.AndersenM
may escalate to 14 mg based on response Must be taken on an empty stomach with a small sip of water (120 ml) and wait 30 minutes before eating, drinking or taking other oral medicines For semaglutide (Wegovy) used in weight management: Gradual escalation over 1620 weeks, starting at 0.25 mg weekly Target maintenance dose: 2.4 mg once weekly Some patients may remain on 1.7 mg if 2.4 mg is not tolerated For dulaglutide (Trulicity) : Starting dose: 0.75 mg once weekly Can be increased to 1.5 mg, 3 mg, or 4.5 mg weekly depending on response For liraglutide (Victoza) in diabetes: Starting dose: 0.6 mg daily for at least one week Maintenance: 1.2 mg daily, with possible increase to 1.8 mg For liraglutide (Saxenda) in weight management: Gradual weekly increases from 0.6 mg to a target of 3 mg daily All GLP-1 medications follow a dose-escalation protocol to minimise gastrointestinal side effects such as nausea, vomiting, and diarrhoea